SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    John Camm, Timothy Hla, Rajesh Bakshi, Volker Brinkmann, Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications, American Heart Journal, 2014,

    CrossRef

  2. 2
    Qiao Cheng, Shoubao Ma, Dandan Lin, Yu Mei, Huanle Gong, Lei Lei, Yuanyuan Chen, Ye Zhao, Bo Hu, Yan Wu, Xiao Yu, Lixiang Zhao, Haiyan Liu, The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment, Cellular and Molecular Immunology, 2014,

    CrossRef

  3. 3
    Maria Podbielska, Naren Banik, Ewa Kurowska, Edward Hogan, Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination, Brain Sciences, 2013, 3, 3, 1282

    CrossRef

  4. 4
    Kenji Chiba, Kunitomo Adachi, Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis, Future Medicinal Chemistry, 2012, 4, 6, 771

    CrossRef

  5. 5
    James B. Moberly, Shashank Rohatagi, Hamim Zahir, Ching Hsu, Robert J. Noveck, Kenneth E. Truitt, Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor-1 Modulator, The Journal of Clinical Pharmacology, 2012, 52, 7
  6. 6
    Kenji Chiba, Narihiko Yoshii, Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera^|^reg;/Gilenya^|^reg;) for the treatment of multiple sclerosis, Folia Pharmacologica Japonica, 2012, 139, 6, 265

    CrossRef

  7. 7
    Kai Wu, Francois Mercier, Olivier J. David, Robert L. Schmouder, Michael Looby, Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants, The Journal of Clinical Pharmacology, 2012, 52, 7
  8. 8
    Carola T. Murphy, Kenneth Nally, Fergus Shanahan, Silvia Melgar, Shining a Light on Intestinal Traffic, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  9. 9
    Maria Podbielska, Hubert Krotkiewski, Edward L. Hogan, Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis, Neurochemical Research, 2012, 37, 6, 1154

    CrossRef

  10. 10
    Jeffrey A. Cohen, Jerold Chun, Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis, Annals of Neurology, 2011, 69, 5
  11. 11
    Mirjam Schuchardt, Markus Tölle, Jasmin Prüfer, Markus van der Giet, Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system, British Journal of Pharmacology, 2011, 163, 6
  12. 12
    David J. Swan, John A. Kirby, Simi Ali, Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation, Journal of Cellular and Molecular Medicine, 2010, 14, 9
  13. 13
    Kenji CHIBA, A New Therapeutic Approach for Autoimmune Diseases by the Sphingosine 1-Phosphate Receptor Modulator, Fingolimod (FTY720), YAKUGAKU ZASSHI, 2009, 129, 6, 655

    CrossRef

  14. 14
    Kangmin D. Lee, Woon N. Chow, Carmen Sato-Bigbee, Martin R. Graf, Robert S. Graham, Raymond J. Colello, Harold F. Young, Bruce E. Mathern, FTY720 Reduces Inflammation and Promotes Functional Recovery after Spinal Cord Injury, Journal of Neurotrauma, 2009, 26, 12, 2335

    CrossRef

  15. 15
    Shashank Rohatagi, Hamim Zahir, James B. Moberly, Kenneth E. Truitt, Shin-ichi Inaba, Takaichi Shimozato, T. J. Carrothers, Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator, The Journal of Clinical Pharmacology, 2009, 49, 1
  16. 16
    Masao Chino, Masatoshi Kiuchi, Kunitomo Adachi, An efficient total synthesis of a sphingosine-1-phosphate receptor agonist KRP-203, Tetrahedron, 2008, 64, 17, 3859

    CrossRef

  17. 17
    Banu Sis, Richard Grynoch, Allan G. Murray, Patricia Campbell, Kim Solez, Antibody-Mediated Rejection With a Striking Interstitial Monocyte/Macrophage Infiltration in a Renal Allograft Under FTY720 Treatment, American Journal of Kidney Diseases, 2008, 51, 1, 127

    CrossRef

  18. 18
    Alejandro Horga, Xavier Montalban, FTY720 (fingolimod) for relapsing multiple sclerosis, Expert Review of Neurotherapeutics, 2008, 8, 5, 699

    CrossRef

  19. 19
    Q. Liu, X. Zhao, F. Frissora, Y. Ma, R. Santhanam, D. Jarjoura, A. Lehman, D. Perrotti, C.-S. Chen, J. T. Dalton, N. Muthusamy, J. C. Byrd, FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma, Blood, 2008, 111, 1, 275

    CrossRef

  20. 20
    Yuk Yuen Lan, Daisuke Tokita, Zhiliang Wang, Hao Chen Wang, Jianghua Zhan, Volker Brinkmann, Angus W. Thomson, Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: Association with prolonged allograft survival, Transplant Immunology, 2008, 20, 1-2, 88

    CrossRef

  21. 21
    Sebastian Martini, Harm Peters, Torsten Böhler, Klemens Budde, Current perspectives on FTY720, Expert Opinion on Investigational Drugs, 2007, 16, 4, 505

    CrossRef

  22. 22
    Torsten Böhler, Manuela Schütz, Klemens Budde, Hans-H. Neumayer, Johannes Waiser, Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients, International Immunopharmacology, 2007, 7, 1, 88

    CrossRef

  23. 23
    J. Klatt, H.-P. Hartung, R. Hohlfeld, FTY720 (Fingolimod) als neue Therapiemöglichkeit der Multiplen Sklerose, Der Nervenarzt, 2007, 78, 10, 1200

    CrossRef

  24. 24
    Fang Wang, Wenfeng Tan, Dunming Guo, Shaoheng He, Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720, European Journal of Pharmacology, 2007, 573, 1-3, 230

    CrossRef

  25. 25
    Lin Yan, Richard Budhu, Pei Huo, Christopher L. Lynch, Jeffrey J. Hale, Sander G. Mills, Richard Hajdu, Carol A. Keohane, Mark J. Rosenbach, James A. Milligan, Gan-Ju Shei, Gary Chrebet, James Bergstrom, Deborah Card, Suzanne M. Mandala, 2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors, Bioorganic & Medicinal Chemistry Letters, 2006, 16, 13, 3564

    CrossRef

  26. 26
    M Germana Sanna, Sheng-Kai Wang, Pedro J Gonzalez-Cabrera, Anthony Don, David Marsolais, Melanie P Matheu, Sindy H Wei, Ian Parker, Euijung Jo, Wei-Chieh Cheng, Michael D Cahalan, Chi-Huey Wong, Hugh Rosen, Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo, Nature Chemical Biology, 2006, 2, 8, 434

    CrossRef

  27. 27
    Klemens Budde, Manuela Schütz, Petra Glander, Harm Peters, Johannes Waiser, Lutz Liefeldt, Hans-H Neumayer, Torsten Böhler, FTY720 (fingolimod) in renal transplantation, Clinical Transplantation, 2006, 20,
  28. 28
    Leonard M.B. Vaessen, Nicole M. van Besouw, Wendy M. Mol, Jan N.M. IJzermans, Willem Weimar, FTY720 treatment of kidney transplant patients: A differential effect on B cells, naïve T cells, memory T cells and NK cells, Transplant Immunology, 2006, 15, 4, 281

    CrossRef

  29. 29
    Helio Tedesco Silva, Paula Pinheiro Machado, Claudia Rosso Felipe, Jose Osmar Medina Pestana, Immunotherapy for De Novo Renal Transplantation, Drugs, 2006, 66, 13, 1665

    CrossRef

  30. 30
    Adam C Yopp, Levi G Ledgerwood, Jordi C Ochando, Jonathan S Bromberg, Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants, Clinical Transplantation, 2006, 20, 6
  31. 31
    Jun Fujishiro, Shinji Kudou, Satomi Iwai, Masafumi Takahashi, Yoji Hakamata, Miki Kinoshita, Satoru Iwanami, Shigeru Izawa, Tokutaro Yasue, Kohei Hashizume, Takashi Murakami, Eiji Kobayashi, Use of Sphingosine-1-Phosphate 1 Receptor Agonist, KRP-203, in Combination with a Subtherapeutic Dose of Cyclosporine A for Rat Renal Transplantation, Transplantation, 2006, 82, 6, 804

    CrossRef

  32. 32
    Takeyuki Kohno, Takumi Tsuji, Kaori Hirayama, Rumi Iwatsuki, Michitaka Hirose, Kazuhito Watabe, Hiroaki Yoshikawa, Tomoko Kohno, Akiko Matsumoto, Tetsuro Fujita, Masatoshi Hayashi, A Novel Immunomodulator, FTY720, Prevents Development of Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice, Biological & Pharmaceutical Bulletin, 2005, 28, 4, 736

    CrossRef

  33. 33
    Masatoshi Kiuchi, Kunitomo Adachi, Ayumi Tomatsu, Masao Chino, Shuzo Takeda, Yoshihito Tanaka, Yasuhiro Maeda, Noriko Sato, Naoko Mitsutomi, Kunio Sugahara, Kenji Chiba, Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate, Bioorganic & Medicinal Chemistry, 2005, 13, 2, 425

    CrossRef

  34. 34
    Jason G. Cyster, CHEMOKINES, SPHINGOSINE-1-PHOSPHATE, AND CELL MIGRATION IN SECONDARY LYMPHOID ORGANS, Annual Review of Immunology, 2005, 23, 1, 127

    CrossRef

  35. 35
    Jin Young Kim, Sun Woo Lim, Can Li, Jung Shim Kim, Kyung Ohk Ahn, Hyun Joo Yang, Bum Soon Choi, Yong Soo Kim, Jin Kim, Byung Kee Bang, Chul Woo Yang, Effect of FTY720 on Chronic Cyclosporine Nephropathy in Rats, Transplantation, 2005, 80, 9, 1323

    CrossRef

  36. 36
    J. M. Kovarik, R. L. Schmouder, D. Serra, Y. Wang, H. Wiegand, S. C. Dilzer, K. C. Lasseter, FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment, The Journal of Clinical Pharmacology, 2005, 45, 4
  37. 37
    Kenji Chiba, FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors, Pharmacology & Therapeutics, 2005, 108, 3, 308

    CrossRef

  38. 38
    Helio Tedesco-Silva, Georges Mourad, Barry D. Kahan, Josep Grinyo Boira, Willem Weimar, Shamkant Mulgaonkar, Bj??rn Nashan, Soren Madsen, Bernard Charpentier, Pascale Pellet, Yves Vanrenterghem, FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation, Transplantation, 2005, 79, 11, 1553

    CrossRef

  39. 39
    Torsten B??hler, Klemens Budde, Hans-H Neumayer, Johannes Waiser, Novel Mediators of FTY720 in Human Lymphocytes, Transplantation, 2005, 79, 4, 492

    CrossRef

  40. 40
    Anamaria Jorga, Atholl Johnston, Novel therapies in transplantation, Expert Opinion on Investigational Drugs, 2005, 14, 3, 295

    CrossRef

  41. 41
    Lev Koyrakh, Maria I. Roman, Volker Brinkmann, Kevin Wickman, The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein-Gated Potassium Channel IKACh, American Journal of Transplantation, 2005, 5, 3
  42. 42
    Yuk Yuen Lan, An De Creus, Bridget L. Colvin, Masanori Abe, Volker Brinkmann, P. Toby H. Coates, Angus W. Thomson, The Sphingosine-1-Phosphate Receptor Agonist FTY720 Modulates Dendritic Cell Trafficking In Vivo, American Journal of Transplantation, 2005, 5, 11
  43. 43
    Tomomi Suzuki, Maeng Bong Jin, Tsuyoshi Shimamura, Kenichiro Yamashita, Masahiko Taniguchi, Masaru Nomura, Ryouichi Yokota, Moto Fukai, Shinichiro Magata, Hiroyuki Horiuchi, Miri Fujita, Kazuro Nagashima, Hiroyuki Furukawa, Satoru Todo, A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments, Transplant International, 2004, 17, 10
  44. 44
    Takeyuki Kohno, Takumi Tsuji, Kaori Hirayama, Kazuhito Watabe, Akiko Matsumoto, Tomoko Kohno, Tetsuro Fujita, A Novel Immunomodulator, FTY720, Prevents Spontaneous Dermatitis in NC/Nga Mice, Biological & Pharmaceutical Bulletin, 2004, 27, 9, 1392

    CrossRef

  45. 45
    Lin Yan, Jeffrey J. Hale, Christopher L. Lynch, Richard Budhu, Amy Gentry, Sander G. Mills, Richard Hajdu, Carol Ann Keohane, Mark J. Rosenbach, James A. Milligan, Gan-Ju Shei, Gary Chrebet, James Bergstrom, Deborah Card, Hugh Rosen, Suzanne M. Mandala, Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) receptors, Bioorganic & Medicinal Chemistry Letters, 2004, 14, 19, 4861

    CrossRef

  46. 46
    T. Bohler, J. Waiser, M. Schuetz, H. H. Neumayer, K. Budde, FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors, Nephrology Dialysis Transplantation, 2004, 19, 3, 702

    CrossRef

  47. 47
    R Ferguson, FTY720 immunomodulation: optimism for improved transplant regimens, Transplantation Proceedings, 2004, 36, 2, S549

    CrossRef

  48. 48
    Grit Schroeder, Kirsten Risch, Katja Kotsch, Anja Siepert, Josef Brock, Peter Nickel, Petra Reinked, Thomas Ritter, Hans-Dieter Volk, Manfred Lehmann, FTY720 Prevents Anti-CD4 mAb-Induced Tolerance but Cannot Reverse Established Tolerance in a Rat Kidney Transplantation Model, American Journal of Transplantation, 2004, 4, 6
  49. 49
    U. Kunzendorf, E. Ziegler, D. Kabelitz, FTY720--the first compound of a new promising class of immunosuppressive drugs, Nephrology Dialysis Transplantation, 2004, 19, 7, 1677

    CrossRef

  50. 50
    Duska Dragun, Torsten Bohler, Melina Nieminen-Kelha, Johannes Waiser, Wolfgang Schneider, Hermann Haller, Friedrich C. Luft, Klemens Budde, Hans-Hellmut Neumayer, FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury, Kidney International, 2004, 65, 3, 1076

    CrossRef

  51. 51
    D Dragun, L Fritsche, T Boehler, H Peters, K Budde, H.H Neumayer, FTY720: early clinical experience, Transplantation Proceedings, 2004, 36, 2, S544

    CrossRef

  52. 52
    John M. Kovarik, Robert Schmouder, Denise Barilla, Yibin Wang, Gerolf Kraus, Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects, British Journal of Clinical Pharmacology, 2004, 57, 5
  53. 53
    Shih-Chieh J. Chueh, Barry D. Kahan, Update on FTY720: review of mechanisms and clinical results, Current Opinion in Organ Transplantation, 2003, 8, 4, 288

    CrossRef